Citi Pharma enters into supply agreement with India’s Murli Krishna PharmaÂ
Murli Krishna Pharma will supply high-quality Active Pharmaceutical Ingredients (APIs) and products exclusively to Citi Pharma in Pakistan
CCP approves acquisition of two Japanese pharma products by Hilton Pharma
Proposed transaction entails the acquisition of Methycobal and Myonal including their trademarks
Sales tax hike to 18% expected to raise medicine prices
Sales tax is also imposed on diagnostic kits/equipment across various specialties, including cardiology, neurology, oncology, and urologyÂ
Hoechst Pakistan to acquire products and trademarks from Sanofi affiliates
Board approves strategic acquisition to strengthen product portfolio and market position
Lucky Core seals deal for Pfizer’s Karachi plant, pharma products
Asset Purchase Agreements signed, acquisition includes products such as Ansaid, Ponstan, Ponstan Forte, Basoquin, Deltacortril, Lysovit, Corex-D, and Mycitracin.Â
Searle Company to divest entire stake in Searle Pakistan Limited
Board approves disposal of 100% shareholding; negotiations for terms underway
Lucky Core Industries expands portfolio with Pfizer assets acquisition
Deal includes a manufacturing facility, certain pharma products and trademarks associated with said products
Citi Pharma, Hangzhou Newsea partner to boost local API manufacturing
With an expected annual turnover of Rs15,000m, the JV underscores a push towards reducing import dependence and enhancing local manufacturing infrastructure in Pakistan’s pharmaceutical industry
Saudi investors exit Pakistan’s largest pharmacy chain. What happened and why?
From its origins as part of the Servis Group to multiple changes in ownership since its inception in 2005, Servaid has undergone an eventful two decades in existence
The magic pill for the pharma sector
Will the deregulation in drug pricing policy prove to be the long awaited cure for the pharmaceutical industry?
AGP acquires portfolio of products from American pharma firm Viatris
AGP claims newly acquired products will add Rs20b to annual revenues
PPMA vs DRAP: Pharma crisis continuesÂ
Unavailability of medicines could inevitably trigger national health emergency
Pricing dispute causes shortage of critical medicine
Pharma companies stop, limit production of scores of essential and non-essential medicines as govt rejects demand for 38% hike in prices
Pfizer looks beyond COVID sales with $43b deal for cancer drugmaker Seagen
WASHNGTON: Pfizer Inc on Monday struck a roughly $43 billion deal for Seagen Inc to bulk up its cancer treatments portfolio, as...
The mechanics behind the panadol shortage
Raids, hoarding and over regulating — You probably need a Panadol to figure out what’s going on